Jsc Nextgen
Clinical trials sponsored by Jsc Nextgen, explained in plain language.
-
Gene therapy aims to heal bladder scarring and prevent shrinkage
Disease control Recruiting nowThis study tests an experimental gene therapy called Neovasculgen in 180 women with a painful bladder condition that includes Hunner's lesions (sores). The goal is to reduce scarring from previous treatments and prevent the bladder from shrinking. Participants receive either the …
Phase: PHASE2, PHASE3 • Sponsor: JSC NextGen • Aim: Disease control
Last updated May 26, 2026 08:06 UTC
-
New drug aims to heal stubborn diabetic foot sores
Disease control Recruiting nowThis study tests a drug called Neovasculgen to see if it can help heal foot ulcers in people with diabetes. About 144 adults with a non-healing foot ulcer will receive the drug or a placebo, plus standard care, for up to 6 months. The main goal is to see if the ulcer completely h…
Phase: PHASE3 • Sponsor: JSC NextGen • Aim: Disease control
Last updated May 26, 2026 07:27 UTC
-
Gene therapy aims to ease chronic bladder pain in new trial
Disease control Recruiting nowThis study tests a gene therapy called Neovasculgen for people with painful bladder syndrome/interstitial cystitis, a condition causing long-term pelvic pain and frequent urination. The trial will include 180 women aged 18 to 65 with confirmed symptoms for at least a year. The go…
Phase: PHASE2, PHASE3 • Sponsor: JSC NextGen • Aim: Disease control
Last updated May 20, 2026 11:56 UTC